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Abstract 
Review on VIP, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: PHM27 
HGNC (Hugo): VIP 
Location: 6q25.2 
Local order: The VIP gene has 7 exons. 
Note: VIP is a secreted protein which binds to 
membrane G-protein coupled receptors (GPCR) 
increasing intracellular cAMP signaling. 
DNA/RNA 
Note 
The human VIP gene encodes 7 exons and is 




The VIP gene spans 8837 bp. 
Transcription 
The gene transcript has 1601 bp. 
Protein 
Description 
Said and Mutt (1970) sequenced an acid extractable 
peptide from the porcine duodenum which 
decreased systemic arterial pressure and increased 
heart rate, stroke volume, mesenteric and femoral 
blood flow in the dog.  
The 27 amino acid peptide was named vasoactive 
intestinal peptide (VIP). VIP is metabolized 
(Bodner et al., 1985) from a 170 amino acid 
precursor protein (preproVIP).  
 
Structure of human preproVIP. VIP is derived from the 170 amino acid precursor protein preproVIP. Initially the signal peptide 
(1-20) is cleaved by signal proteases to generate proVIP. ProVIP (22-170) is metabolized to (22-79), PHM (81-107), (111-122), 
VIP (125-152) and (156-170) by prohormone convertases. Carboxypeptidase B-like enzymes cleave basic R and K. The C-
terminal of PHM and VIP is amidated when G is metabolized by peptidylglycine alpha-amidating monooxygenase (PAM) 
enzymes. 
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Each exon encodes a distinct domain of the 
preproVIP 5' untranslated regions of the mRNA 
(exon I); signal peptide of preproVIP (exon II); N-
terminal peptide (exon III); peptide histidine 
methionine (PHM) (exon IV); VIP (exon V); C-
terminal of preproVIP (exon VI); untranslated 
region of the mRNA (exon VII). VIP and PHM, 
which have 48% amino acid homology, are in 
adjacent exons and the introns surrounding these 
exons are highly conserved. 
The substrate prepro-VIP is initially metabolized by 
a signal protease to form the product 149 amino 
acid pro-VIP. Pro-VIP is metabolized by 
prohormone convertases to VIP-GKR 
(preproVIP(125-155)) and PHM-GKR 
(preproVIP(81-110)).  
The basic amino acids are cleaved by 
carboxypeptidase B and the G is metabolized to an 
amide by PAM enzymes. Thus the N-terminal of 
VIP and PHM is free whereas the C-terminal is 
amidated. VIP is structurally related to pituitary 
adenylate cyclase activating polypeptide (PACAP) 
(Arimura, 1992). VIP has a β-turn at residues 2-5 
and 7-10 followed by an α-helix at residues 11-26 
(Vaudry et al., 2009).  
VIP binds with high affinity to 2 GPCR (VPAC1 
and VPAC2) which are members of the class II or 
class B secretin-like receptors but not PAC1 which 
binds PACAP with high affinity (Harmar et al., 
2012). The activated VPAC1 or VPAC2 interacts 
with a stimulatory guanine nucleotide binding 
protein (Gs) causing increased adenylylcyclase 
activity resulting in elevated cAMP. The increased 
cAMP activates protein kinase (PK) A causing 
phosphorylation of various proteins such as CREB 
leading to altered gene expression. 
Expression 
VIP is produced in neurons within the adrenals, 
brain, gastrointestinal (GI) tract, heart, pituitary nd 
pancreas (Sundler et al., 1988). VIP addition to the 
adrenals causes catecholamine release (Card et al., 
1988). VIP expression in the suprachiasmatic 
nucleus of the brain is altered by light-dark cycles 
(Gozes et al., 1989) suggesting that it may play a 
role in circadian cycles. VIP reduction in knockout 
mice is associated with human motility disorders 
(Moody et al., 2011). In the heart, VIP-containing 
nerve fibers are abundant in arteries but not veins 
and venules (Sundler et al., 1988). VIP secretion 
from pancreatic neurons alters enzyme and 
electrolyte secretion (Konturek et al., 1976). In the 
pituitary, VIP gene expression is regulated by 
estrogen leading to altered prolactin secretion 
(Montagne et al., 1995). VIP is present in and 
secreted from immune cells especially Th2 cells 
altering cytokine and chemokine production 
(Gonzalez-Rey et al., 2007). The VIP gene is in 
NSCLC cells and its expression is regulated in a 
PKC and cAMP dependent manner (Davidson et 
al., 1996). VIP is present in neuroblastoma and 
pheochromocytoma (Beinfeld et al., 1988). The 
results indicate that VIP is present in normal 
neurons and cancer cells. 
Localisation 
PreproVIP is stored in dense core neurosecretory 
granules in cells. PHM, proVIP and VIP are 
secreted when cAMP is elevated. While VIP has 
potent biological activity, PHM and proVIP are also 
active (Fahrenkrug, 1991). In NSCLC cells, the 
ratio of PHM/ proVIP/VIP is 1/3/1 respectively 
(Moody et al., 2003). VIP is metabolized by neutral 
endopeptidase and has a half life of 2 min (Henning 
and Sawmiller, 2001). 
Function 
VIP is a cotransmitter with nitric oxide and carbon 
monoxide of nonadrenergic, noncholinergic 
vascular and nonvascular smooth muscle (Said and 
Rattan, 2004).  
It is a cotransmitter with acetylcholine in exocrine 
glands (Fahrenkrug, 1993). VIP promotes neuronal 
survival (Brenneman and Eiden, 1986). VIP causes 
prolactin secretion from the pituitary (Reichlin, 
1988) and catecholamine release from the adrenal 
medulla (Malhotra et al., 1988). In the immune 
system VIP regulates T cell traffic and proliferation 
(Ottaway, 1987). 
Homology 
VIP has 67% sequence homology with PACAP-27. 
The sequence for VIP is identical in the human, 
bovine, porcine and rat. 
Mutations 
Note 
The VIP gene is altered in patients with idiopathic 
pulmonary arterial hypertension (IPAH) (Haberl et 
al., 2007). The 3' untranslated region in exon 7 is 
mutated (g.8129T>C) leading to reduced VIP 
serum levels and higher pulmonary artery pressure 




VIPomas were described by Verner and Morrison 
(1958).  
Most of the VIPomas occur in the pancreas leading 
to diarrheal fluid similar to that seen in patient wi h 
cholera, hence the term pancreatic cholera of 
watery diarrhea, hypokalemic and achlorhydric 
(WDHA) has been used. The plasma VIP levels are 
significantly elevated in patients with VIPomas 
(Long et al., 1981). 
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Lung cancer 
Note 
The VIP gene is expressed in numerous lung cancer 
cell lines (Davidson et al., 1996). Pro-VIP and VIP 
are present in lung cancer cell lines (Moody et al., 
2003). VIP (10 nM) increases lung cancer colony 
formation which is inhibited by the VPAC1 
antagonist VIPhybrid (Moody et al., 1993). High 
densities of VPAC1 are present in lung cancer cells 
(Moody and Gozes, 2007). 
Breast cancer 
Note 
VIP addition to breast cancer cells causes 
transactivation of the EGF receptor and HER2 
(Valdehita et al., 2009). Addition of VIP-
camptothecin conjugates causes apoptosis of breast 
cancer cells (Moody et al., 2007). 
Renal cell carcinoma 
Note 
Addition of 100 nM VIP to renal cancer cells 
decreases proliferation (Vacas et al., 2012). High 
concentrations of VIP may cause differentiation of 
cancer cells (Hoosein et al., 1989). 
Prostate cancer 
Note 
High densities of VPAC1 were detected in prostate 
cancer cell lines (Reubi et al., 2000). 
Colon cancer 
Note 
123I-VIP can be used to visualize colon cancer 
tumors in patients (Raderer et al., 1998). 
Diabetes 
Note 
Overexpression of the VIP gene in mouse 
pancreatic beta cells resulted in reduced blood 
glucose and insensitivity to glucose intolerance 
(Passemard et al., 2011). 
Bronchial asthma 
Note 
VIP nerves are absent in severely asthmatic 
subjects. Mice with targeted deletion of the VIP 
gene exhibit histopathologic features of airway 
inflammation (Said et al., 2010). 
Cardiomyopathy 
Note 
Hearts were dilated in VIP knockout mice with 
thinning of the left ventricular wall and increases in 
right ventricular and left ventricular chamber size 
resulting from overexpression of cardiomyophathy 
genes (Szema et al., 2013). VIP is a potent 
vasodilator and increases the heart rate (Henning 
and Sawmiller, 2001). 
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